Categories
Health

Big Survival Gain in EGFR-Mutant NSCLC

Source link : https://newshealth.biz/health-news/big-survival-gain-in-egfr-mutant-nsclc/

PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib in advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC). More specifically, the combination led to a statistically significant and clinically meaningful reduction in mortality compared […]

The post Big Survival Gain in EGFR-Mutant NSCLC first appeared on News Health.

Author : News Health

Publish date : 2025-03-28 08:24:00

Copyright for syndicated content belongs to the linked Source.

.. . . . . . . . . . . . . . . . . . . . . . . . . ***. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ - - - - - - - - - - - - - - - - - - - - . . . . .